CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 21 enrolled
Drug / intervention
selumetinib 75mg single dose +1 moredrug
Likely dose
selumetinib 75mg single dosefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02238782
NCT02238782Phase 1Completed

A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Selumetinib With Respect to an Intravenous Microdose of [14C] Selumetinib in Healthy Male Volunteers

AstraZeneca·interventional·Posted Sep 12, 2014·Updated Apr 5, 2016

In Brief

A Phase 1 clinical trial evaluating selumetinib 75mg single dose and [14C] selumetinib IV solution for Healthy Volunteers Bioavailability Study. Completed, enrolled 21 participants across 1 site.

Detailed Summary

To assess the absolute bioavailability of oral selumetinib in healthy male volunteers

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 12, 2014
Enrollment StartOct 1, 2014
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 11.8 years ago

Interventions

selumetinib 75mg single dosedrug

3 capsules of 25 mg given as a single dose

[14C] selumetinib IV solutionother

single, radiolabeled, IV (infused), microdose (80 μg) of \[14C\] selumetinib, infused using a syringe pump as a 15-minute infusion, administered 1h 15 min after receiving the oral dose